Pugang Pharmaceutical Corporation: Russia Operations Status & Business Impact
LeaveRussia detail: Continue Operations
Korea Pugang Corporation (Korean: 조선부강회사) is a North Korean holding company founded in 1979. Pugang Pharmaceutic Company (Korean: 부강제약회사; 富强製藥會社) is a pharmaceutical company founded in 1983. It is operated by North Korea's Ministry of Public Health. Although the company had its assets frozen as a result of U.S. sanctions, its products are sold internationally by Lekar Korea, a distributor based in Russia.
Business in Russia
North Korea plans to sell its drugs in Russia, which treat everything from insomnia to leukemia. Of course, their effectiveness hasn't been proven.
Decision trail
Decision date 27/05/2025 · Reference ↗
Krasnodar company "Gradient" imports to Russia the injectable dietary supplement "Kumdan-2", produced by North Korean Pugang Pharmaceutical Corporation, according to data from the Federal Accreditation Service. The DPRK authorities advertise this product as a universal cure for all diseases - MERS, SARS and even HIV/AIDS.
Status history since 2022
- 03/08/2026 — operating · Imported from KSE LeaveRussia
Exposure profile
Get alerts if this company's Russia status changes
7-day Pro trial includes watchlists for companies you track. No credit card. Full exposure maps are on Professional after the trial.
Start 7-day Pro trialGeopolitical context and sanctions impact
Pugang Pharmaceutical Corporation is a Pharma & Healthcare company based in North Korea. Current Russia status in our dataset is operating: continued operations in Russia remain a compliance, reputational and counterparties risk for EU and allied firms. Eastern Europe Impact translates those facts into business consequences — sanctions screening, supply-chain exposure and reconstruction-side opportunity — with transparent confidence labels rather than speculation.
Risk assessment and how to use this profile
Start with the status badge and decision trail, then check possible sanctions matches and recent events mentioning Pugang Pharmaceutical Corporation. A 7-day Pro trial adds watchlists so you are notified if Russia status, designations or linked events change. Full exposure maps (energy, transport, commodities) are on Professional. This page is risk information, not legal or investment advice.
Questions about Pugang Pharmaceutical Corporation
What kind of data does Eastern Europe Impact provide on Pugang Pharmaceutical Corporation?
- Eastern Europe Impact publishes verified intelligence on Pugang Pharmaceutical Corporation's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.
How can Eastern Europe Impact data on Pugang Pharmaceutical Corporation help my business?
- Use the Pugang Pharmaceutical Corporation profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.
How do we verify the information on Pugang Pharmaceutical Corporation?
- We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.
How much does Eastern Europe Impact cost?
- The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.